Thrombolytic therapy of fibrinolysin

A technology of plasmin and fibrin, which is applied in the field of medicine and can solve problems such as short half-life

Inactive Publication Date: 2015-04-15
SHANGHAI MANYI TECH
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

TPA has been found to have ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach

[0015] One of the major problems with plasminogen activator dosing is the lytic state that accompanies high concentrations of infused streptokinase or, to a lesser extent, tissue plasminogen activator. This is due to the generation of plasminogen activator plasminogen circulating in humans or animals. Tissue plasminogen activator has a certain affinity for fibrin, allowing activation to occur preferentially in this area of ​​the clot.

[0016] Purified plasmin receptors which are the subject of the present invention can be used in combination with plasminogen activators to produce the desired thrombolytic activity. Advantageously, using the plasmin receptor, can be used to reduce the amount of plasminogen activator required to achieve the necessary activity. By binding the plasminogen activator produced with plasmin, the receptor is able to greatly prolong the effect of the plasminogen activator. Adverse effects of plasminogen activators are thus minimized due to their short...

Embodiment 1

[0047] human plasmin

[0048] Sephadex G-100 molecular sieve chromatography (Lottenberg, R., F. R. Dolly, C. S. Kitchens [1985] Am. J. Hematol . 19:181-193). Purified protein showed a single band on silver-stained SDS-polyacrylamide gel electrophoresis. Activation of the isolated human plasminogen with streptokinase at a given concentration demonstrated the predicted theoretical amidolytic activity, thus confirming the purity of the isolated human plasminogen.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a novel thrombolytic therapy of fibrinolysin, and more particularly discloses a high-affinity receptor of the fibrinolysin. The receptor is characterized by comprising steps of purification, clone and expression. The receptor can be used before drug administration or, at the same time, used in a combination therapy of a fibrinolysin zymogen activator after drug administration. In addition, the receptor can be bounded with fibrinolysin and takes charge of human or animals who need fibrinolytic activity. The invention further relates to novel immobilized fibrinolysin having anti-fibrinolysis activity, on which point more advantageous accumulation is needed.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a thrombolytic therapy method for plasmin. Background technique [0002] Ten years ago, the Food and Drug Administration approved the use of plasminogen activator thrombolytic therapy. It was originally recommended for the treatment of deep vein thrombosis and severe pulmonary embolism. This approach is now also used in the treatment of acute peripheral arterial thrombosis and acute coronary thrombosis and thrombolytic catheters and shunts. [0003] With the development of recombinant DNA technology and the cloning and expression of tissue plasminogen activator (TPA), we have now entered a new era of thrombolytic agents with unique physiological properties and therapeutic promise. The original plasminogen activators, which have been used clinically, are streptokinase and urokinase. These drugs produce a wide variety of side effects in patients and are not directly aimed at dissolving f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/02A61P7/02
Inventor 陈晴川
Owner SHANGHAI MANYI TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap